From MT-2 to PT-141
PT-141 (bremelanotide) was developed as a metabolite analog of MT-2 with improved selectivity for the MC4R pathway. The structural modification — replacing the C-terminal amide with a hydroxyl group and adjusting the cyclic ring — reduces MC1R affinity while preserving MC4R binding. This selectivity makes PT-141 more targeted for CNS pathway research and eliminates the pigmentation side effects associated with broad MC receptor activation.
MC4R Mechanism in Sexual Function Research
MC4R activation in the paraventricular nucleus triggers a cascade involving dopamine and oxytocin release that facilitates sexual arousal and erection physiology in animal models. Unlike PDE5 inhibitors (sildenafil, tadalafil), which work peripherally by increasing blood flow, PT-141 acts centrally on the CNS arousal pathway. This central mechanism is what makes it interesting for research models where vascular etiology is not the primary variable.
Clinical Development: FDA Approval
PT-141/bremelanotide received FDA approval in 2019 (marketed as Vyleesi) for hypoactive sexual desire disorder in premenopausal women — making it one of the few research peptides to complete the full clinical development pipeline. The approved formulation is a subcutaneous auto-injector administered 45 minutes before sexual activity. This clinical track record provides robust human pharmacokinetic and safety data that researchers can reference.
Selectivity vs. MT-2 in Research Design
When designing research that isolates MC4R-mediated CNS effects, PT-141 is preferred over MT-2. MT-2's broad MC1R activation creates confounding pigmentation and adrenal effects that complicate endpoint interpretation. PT-141's relative MC4R selectivity (it is not completely selective, but significantly more so than MT-2) allows cleaner attribution of outcomes to the CNS melanocortin pathway.
Documentation Standards
PT-141 is a 7-amino acid cyclic peptide with MW ~1,025.2 Da. As with MT-2, the cyclic structure must be intact — MS confirmation of the correct molecular ion is required. HPLC purity ≥98%. Because PT-141 and MT-2 are structurally similar, a COA without MS identity confirmation cannot confirm which compound is present.